Foscenvivint (PRI 724 or OP 724) is a CREB-binding protein/β-catenin inhibitor that is developed for the treatment of liver diseases such as primary biliary cholangitis, hepatocellular carcinoma, and hepatitis C and B virus-induced liver cirrhosis.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.